42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study - Concepedia

Concepedia

Publication | Closed Access

42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study

66

Citations

26

References

2019

Year

George G. Zhanel, Heather J. Adam, Melanie Baxter, Jeff Fuller, Kimberly A. Nichol, Andrew Denisuik, Alyssa Golden, Rachel Hink, Philippe Lagacé‐Wiens, Andrew Walkty,

Journal of Antimicrobial Chemotherapy

Abstract

The CANWARD surveillance study has provided 10 years of reference antimicrobial susceptibility testing data on pathogens commonly causing infections in patients attending Canadian hospitals.

References

	Year	Citations
Global increase and geographic convergence in antibiotic consumption between 2000 and 2015 Eili Klein, Thomas P. Van Boeckel, Elena Martínez, Proceedings of the National Academy of Sciences	2018	3.1K
Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial F. Meunier, H. G. Prentice, Olle Ringdén Journal of Antimicrobial Chemotherapy	1991	245
Molecular epidemiology of extended-spectrum -lactamase-, AmpC -lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11 Andrew Denisuik, Philippe Lagacé‐Wiens, Johann Pitout, Journal of Antimicrobial Chemotherapy	2013	153
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study George G. Zhanel, Heather J. Adam, Melanie Baxter, Journal of Antimicrobial Chemotherapy	2013	150
Networking of Public Health Microbiology Laboratories Bolsters Europe’s Defenses against Infectious Diseases Barbara Albiger, Joana Revez, Katrin Leitmeyer, Frontiers in Public Health	2018	136
Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance James A. Karlowsky, Kim Nichol, George G. Zhanel Clinical Infectious Diseases ImmunologyPharmacotherapyVancomycin-resistant S. AureusAntimicrobial ChemotherapyDrug Resistance	2015	94
Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin <i>in vitro</i> potency Rodrigo E. Mendes, Mariana Castanheira, David J. Farrell, Journal of Antimicrobial Chemotherapy	2016	78
Carbapenem-Nonsusceptible <i>Acinetobacter baumannii</i> , 8 US Metropolitan Areas, 2012–2015 Sandra N. Bulens, Sarah H. Yi, Maroya Spalding Walters, Emerging infectious diseases	2018	78
Antimicrobial Activity and Spectrum of Cefovecin, a New Extended- Spectrum Cephalosporin, against Pathogens Collected from Dogs and Cats in Europe and North America Michael Stegemann, C. A. Passmore, J. Sherington, Antimicrobial Agents and Chemotherapy Escherichia ColiVeterinary MicrobiologyAntimicrobial ChemotherapyDrug ResistanceInfection Control	2006	75
Surveillance for linezolid resistance via the Zyvox<sup>®</sup>Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates Rodrigo E. Mendes, Patricia A. Hogan, Ronald N. Jones, Journal of Antimicrobial Chemotherapy	2016	72

Page 1